Canaccord Genuity Gives Buy Rating to Impax Laboratories (IPXL)
Impax Laboratories traded down 3.57% on Thursday, hitting $19.99. Impax Laboratories has a 52-week low of $14.46 and a 52-week high of $28.75. The company has a market cap of $1.307 billion and a price-to-earnings ratio of 22.08.
Impax Laboratories last announced its earnings results on Tuesday, May 1st. The company reported $0.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.45 by $0.07. The company’s quarterly revenue was up 18.3% on a year-over-year basis. On average, analysts predict that Impax Laboratories will post $0.43 earnings per share next quarter.
Several other analysts have also recently commented on the stock. Analysts at Auriga reiterated a “buy” rating on shares of Impax Laboratories in a research note to investors on Monday, May 14th. Separately, analysts at Needham & Company reiterated a “hold” rating on shares of Impax Laboratories in a research note to investors on Wednesday, May 2nd.
Impax Laboratories, Inc. (Impax) is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products.